https://www.selleckchem.com/pr....oducts/syrosingopine
The cause-specific and overall survival rates were 100% and 96.8% at 3years, and 100% and 96.8% at 5years, respectively. There was no local tumor progression or distant metastasis. The incidence of severe urological (urinary fistula and perinephric infection) and non-urological adverse events (increased creatine kinase and skin ulceration) was 6% each. Percutaneous cryoablation for renal cell carcinoma ≤ 4cm in diameter achieved good tumor control with a low complication frequency. Percutaneous cryoablation for renal cell
Like
Comment
Share
